NO20090574L - Nye proteinkonjugater og fremgangsmater for fremstilling derav - Google Patents

Nye proteinkonjugater og fremgangsmater for fremstilling derav

Info

Publication number
NO20090574L
NO20090574L NO20090574A NO20090574A NO20090574L NO 20090574 L NO20090574 L NO 20090574L NO 20090574 A NO20090574 A NO 20090574A NO 20090574 A NO20090574 A NO 20090574A NO 20090574 L NO20090574 L NO 20090574L
Authority
NO
Norway
Prior art keywords
protein conjugates
processes
preparation
novel protein
heteroarylamines
Prior art date
Application number
NO20090574A
Other languages
English (en)
Norwegian (no)
Inventor
Florencio Zaragoza Dorwald
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of NO20090574L publication Critical patent/NO20090574L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20090574A 2006-07-07 2009-02-05 Nye proteinkonjugater og fremgangsmater for fremstilling derav NO20090574L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116776 2006-07-07
PCT/EP2007/056819 WO2008003750A2 (en) 2006-07-07 2007-07-05 New protein conjugates and methods for their preparation

Publications (1)

Publication Number Publication Date
NO20090574L true NO20090574L (no) 2009-03-30

Family

ID=38701511

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090574A NO20090574L (no) 2006-07-07 2009-02-05 Nye proteinkonjugater og fremgangsmater for fremstilling derav

Country Status (15)

Country Link
US (1) US9175061B2 (pt)
EP (1) EP2040757A2 (pt)
JP (1) JP5252458B2 (pt)
KR (1) KR20100014215A (pt)
CN (1) CN101495155A (pt)
AU (1) AU2007271150A1 (pt)
BR (1) BRPI0713963A2 (pt)
CA (1) CA2655188A1 (pt)
IL (1) IL195839A0 (pt)
MX (1) MX2008016169A (pt)
NO (1) NO20090574L (pt)
RU (1) RU2009103198A (pt)
TW (1) TW200815477A (pt)
WO (1) WO2008003750A2 (pt)
ZA (1) ZA200810821B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
CA2359345A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
MX2011000847A (es) * 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (en) * 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr) * 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
BR112013018628A2 (pt) * 2011-01-26 2017-07-18 Novo Nordisk As derivados da leptina
EP2842546A4 (en) 2012-04-27 2015-12-30 Univ Tokyo PHARMACEUTICAL COMPOSITION WITH UNIT STRUCTURE FOR NUCLEIC ACID RELIEF
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2016034534A1 (en) * 2014-09-01 2016-03-10 Novo Nordisk Health Care Ag Lysine rich basic pre-sequences
US10400066B2 (en) 2015-01-27 2019-09-03 Hewlett-Packard Development Company, L.P. Polymeric photoactive agents
WO2016122452A1 (en) * 2015-01-27 2016-08-04 Hewlett-Packard Development Company, L.P. Polymeric amine synergists
WO2016122454A1 (en) 2015-01-27 2016-08-04 Hewlett-Packard Development Company, L.P. Polymeric photo active agents
CN111050752B (zh) 2017-08-31 2022-08-16 国立大学法人东京大学 搭载核酸的单元型聚离子复合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
CA1259923A (en) 1983-08-17 1989-09-26 Roger Aston Physiologically active compositions
US6673347B1 (en) * 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
DE68924783T2 (de) 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
DE69232847T2 (de) 1991-12-20 2003-09-11 Novo Nordisk A/S, Bagsvaerd Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1995032003A1 (en) 1994-05-24 1995-11-30 Amgen Boulder Inc. Modified insulin-like growth factors
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
US5795560A (en) * 1994-11-01 1998-08-18 Neorx Corporation Targeting protein-diagnostic/therapeutic agent conjugates having Schiff base linkages
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
FI972443A7 (fi) * 1994-12-07 1997-06-09 Novozymes As Polypeptidi, jonka allergeenisuus on vähentynyt
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
EP0964702B1 (en) * 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
CN1231675A (zh) 1996-09-26 1999-10-13 味之素株式会社 修饰的生理活性蛋白及含有该蛋白的药物组合物
US6340461B1 (en) 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US6800728B2 (en) 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
JP2004501191A (ja) * 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US7049285B2 (en) * 2001-10-31 2006-05-23 Myung-Ok Park Biocompatible polymers including peptide spacer
WO2003044056A2 (en) 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates
UA86744C2 (en) 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
AU2003256566A1 (en) 2002-07-16 2004-02-02 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
JP4430344B2 (ja) * 2002-09-09 2010-03-10 独立行政法人科学技術振興機構 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
CA2527665A1 (en) 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
BRPI0412671A (pt) 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
CN1528797A (zh) 2003-09-28 2004-09-15 石油大学(华东) 含氟碳基团的超高分子量水溶性疏水缔合型聚合物及其制备方法
JP2008502301A (ja) * 2003-10-10 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ ペプチドの抱合
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
CN1243022C (zh) 2003-10-17 2006-02-22 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
KR20070027621A (ko) * 2004-06-08 2007-03-09 알자 코포레이션 4-성분 축합 반응에 의한 고분자 콘쥬게이트의 제조
EP1805217A2 (en) 2004-10-18 2007-07-11 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
JP2008516621A (ja) 2004-10-18 2008-05-22 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン結合体
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
MX2007015676A (es) 2005-06-15 2008-02-20 Novo Nordisk Healthcare Ag Conjugacion de la hormona de crecimiento mediada por transglutaminasa.
US8293708B2 (en) * 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
AU2006201635A1 (en) * 2005-10-20 2007-05-10 Ludwig Institute For Cancer Research Novel inhibitors and methods for their preparation

Also Published As

Publication number Publication date
IL195839A0 (en) 2009-09-01
CN101495155A (zh) 2009-07-29
WO2008003750A2 (en) 2008-01-10
TW200815477A (en) 2008-04-01
BRPI0713963A2 (pt) 2012-11-27
JP5252458B2 (ja) 2013-07-31
WO2008003750A3 (en) 2008-03-20
US20110144017A1 (en) 2011-06-16
MX2008016169A (es) 2009-01-15
RU2009103198A (ru) 2010-08-20
CA2655188A1 (en) 2008-01-10
EP2040757A2 (en) 2009-04-01
KR20100014215A (ko) 2010-02-10
US9175061B2 (en) 2015-11-03
JP2009542769A (ja) 2009-12-03
ZA200810821B (en) 2009-12-30
AU2007271150A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
NO20090574L (no) Nye proteinkonjugater og fremgangsmater for fremstilling derav
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
NO20092611L (no) Krystallinsk faststoff Rasagilin base
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
MX350375B (es) Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas.
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
CR20120371A (es) Antagonistas de pcsk9
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
DK2135091T3 (da) MS-fremgangsmåder til evaluering af glykaner
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CY1118640T1 (el) Μορια αντισωματος που εχουν ειδικοτητα προσδεσης για την ανθρωπινη il-13
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
BRPI0508064A (pt) flavivìrus, composição de vacina e molécula de ácido nucléico
WO2011019932A3 (en) Compositions and methods for the therapy and diagnosis of influenza
CU20120021A7 (es) Derivados amido espirocíclicos
CY1115577T1 (el) Μεθοδος για την παρασκευη εναντιομερικως καθαρων αμινων
BRPI0815378A2 (pt) as160 como proteína do tipo as160, sistemas de teste, métodos e usos envolvendo a mesma para identificação de terapêutica para diabetes tipo 2
BRPI0721386B8 (pt) Processo para preparação de 2-substituídas -5-(1-alquiltio)-alquil piridinas, e intermediário
BR112012013325A2 (pt) Composição farmacêutica e uso
BRPI0921371A2 (pt) Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.
NO20091386L (no) Fenyloksyanilinderivater